Drug Trial Radar · NCT03536637
DMT310-001 Topical in the Treatment of Acne Vulgaris
Last checked: Nov 19, 2026Latest source record: Jul 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
121
Actual
Start
May 22, 2018
Primary completion
Dec 30, 2018
Study completion Jan 28, 2019
Sponsor
- Lead sponsor
- Dermata TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- May 25, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris.
Conditions
- Acne Vulgaris
Interventions
DMT310Drug
Topical Powder
Hydrogen PeroxideDrug
Liquid Diluent
PlaceboDrug
Placebo Topical Powder
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy as measured by lesion countsTime frame: 12 weeks
- Efficacy as measured by Investigator Global Assessment (IGA)Time frame: 12 weeks
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Dermata Investigational Site
San Diego, California
Dermata Investigational Site
Saint Joseph, Missouri
Dermata Investigational Site
Henderson, Nevada
Dermata Investigational Site
Albuquerque, New Mexico
Dermata Investigational Site
High Point, North Carolina
Dermata Investigational Site
Tennessee City, Tennessee
Dermata Investigational Site
Austin, Texas
Dermata Investigational Site
College Station, Texas
Dermata Investigational Site
Katy, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.